DOUGLAS RICHARD 4

What Happened
Douglas Richard, a director of Aldeyra Therapeutics (ALDX), received three derivative equity awards on 2026-06-09 totaling 92,232 shares (70,000; 19,909; and 2,323). Each grant was reported as acquired at $0.00 per share (grant price $0) and is recorded as a derivative award (code A). The awards vest/exercise rights become 100% exercisable on the one‑year anniversary of the grant date, subject to continued service in the specified board roles.

Key Details

• Transaction date: 2026-06-09; filing date: 2026-06-11 (timely within standard reporting window).
• Grants: 70,000; 19,909; and 2,323 derivative shares — total 92,232 shares; acquisition price $0.00 each.
• Transaction type: A = Award/Grant of derivative securities.
• Vesting/exercise conditions (footnotes):
  • F1: 100% exercisable one year after grant if continuous service as a Board member.
  • F2: 100% exercisable one year after grant if continuous service as Chairperson.
  • F3: 100% exercisable one year after grant if continuous service as a member of the Nominating/Corporate Governance Committee.
• Shares owned after the transaction: not provided in the data supplied here.

Context
These are compensatory derivative awards (board-equity grants) rather than open‑market purchases or sales. They do not involve immediate cash proceeds or sales of shares; vesting is contingent on continued service, so they are typical director compensation and not direct market purchases that signal immediate insider buying.